MedTrace Logo

Propionic Acid in Multiple Sclerosis

NCT06402487 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 101

Last updated 2024-10-15

No results posted yet for this study

Summary

The purpose of this study is to demonstrate the superiority of propionic acid over placebo as add on treatment in multiple sclerosis (MS).

Conditions

Interventions

DIETARY_SUPPLEMENT

Propionic acid 1000 mg capsule

Patients will be assigned to propionic acid or placebo as add on MS treatment.

DIETARY_SUPPLEMENT

Placebo

Patients will be assigned to propionic acid or placebo as add on MS treatment.

Sponsors & Collaborators

  • Salzburger Landeskliniken

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-05-01
Primary Completion
2024-09-15
Completion
2024-10-09

Countries

  • Austria

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06402487 on ClinicalTrials.gov